Table 2.
Model | No. of Events/No. at Risk | TSH, mU/L |
Free T4, pmol/L |
Total T3, nmol/L |
||||||
---|---|---|---|---|---|---|---|---|---|---|
HR | 95% CI | P Value | HR | 95% CI | P Value | HR | 95% CI | P Value | ||
Atrial fibrillation | 812/2673 | |||||||||
Model 1 | 0.94 | 0.87–1.01 | .09 | 1.06 | 1.03–1.10 | <.001 | 0.90 | 0.70–1.15 | .40 | |
Model 2 | 0.94 | 0.87–1.02 | .12 | 1.04 | 1.01–1.08 | .02 | 0.86 | 0.67–1.11 | .24 | |
Coronary heart disease | 786/2215 | |||||||||
Model 1 | 0.95 | 0.88–1.03 | .20 | 1.03 | 0.99–1.06 | .13 | 1.23 | 0.97–1.56 | .09 | |
Model 2 | 0.95 | 0.88–1.02 | .15 | 1.02 | 0.98–1.05 | .28 | 1.13 | 0.89–1.45 | .31 | |
Heart failure | 870/2706 | |||||||||
Model 1 | 0.95 | 0.88–1.02 | .17 | 1.05 | 1.02–1.09 | .004 | 1.07 | 0.85–1.35 | .54 | |
Model 2 | 0.94 | 0.87–1.01 | .09 | 1.04 | 1.00–1.07 | .03 | 1.04 | 0.82–1.32 | .77 | |
Composite cardiovascular outcome | 1128/2073 | |||||||||
Model 1 | 0.94 | 0.88–1.00 | .05 | 1.04 | 1.01–1.07 | .008 | 1.09 | 0.89–1.33 | .43 | |
Model 2 | 0.94 | 0.88–1.00 | .04 | 1.03 | 1.00–1.06 | .02 | 0.97 | 0.79–1.19 | .78 |
Model 1 for all outcomes is adjusted for age, sex, race and initiation of thyroid meds (time-varying).
Model 2 for atrial fibrillation additionally adjusted for BMI, hypertension, fasting glucose, current smoking, any alcohol use, valvular disease history, and use of any diuretic or β blocker.
Model 2 for coronary heart disease additionally adjusted for BMI, hypertension, diabetes, current smoking, low-density lipoprotein cholesterol, lipid lowering medication use, and C-reactive protein.
Model 2 for heart failure additionally adjusted for BMI, hypertension, diabetes, current smoking, coronary heart disease, atrial fibrillation, stroke, claudication, any alcohol use, and creatinine (natural log).
Model 2 for composite cardiovascular disease outcome additionally adjusted for BMI, hypertension, diabetes, stroke, claudication, current smoking, C-reactive protein, and creatinine.